Loading data for GLSI — first visit, this takes a few seconds.

Greenwich LifeSciences, Inc. (GLSI)

NasdaqCM: GLSI · 即時價格 · USD

15.95

+0.32 (2.05%)

收盤價： Sep 08, 2026, 8:00 PM

15.64

-1.64%

盤後: 4:14 PM

提醒

Alert

股價、關鍵數字和最新消息，都在這一頁。

無可用資料

買價	11.28
市值	233M
營收 (ttm)	n/a
淨利（ttm）	-22.5M
	1.46
	-1.6
	n/a
	-19.39
P/B (ttm)	75.00
P/S (ttm)	0.00
財報日期	Nov 12, 2026

賣價	20.09
成交量	65,124
20 日平均成交量	146,211
開盤價	15.45
前收盤價	15.63
當日區間	15.45 - 15.98
52 週範圍	7.78 - 34.10
分析師	n/a
目標價	n/a
股利	n/a
除息日	n/a

關於 GLSI

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I clinical trial designed to ev...

[閱讀更多]

產業 Biotechnology

類股 Healthcare

IPO 日期 Sep 25, 2020

員工 n/a

證券交易所 NasdaqCM

股票代號 GLSI

網站 https://greenwichlifesciences.com

完整的公司簡介

財務表現

Greenwich LifeSciences 在 2025 年的營收為 0，較前一年的 0 增加 undefined%。淨利為 -19.36M，較前期增加 11.16%。

財務報表

財報驚奇

Greenwich LifeSciences 已於 Aug 11, 2026 公布季度財報：

營收為 $0 低於預期 $0, 年增 NaN% 成長.
每股盈餘為 -0.27 超出預期 0.06, 年增 10.00% 成長.

下次財報發布

Greenwich LifeSciences, Inc. 的下次財報預計於 Nov 12, 2026, 盤中。
分析師預估營收 ... 升級

價格為何變動

新聞動態

3 月前 · Stocktwits

GLSI Stock Climbs After Removing A Key Overhang – Retail Turns Focus To High-Stakes Breast Cancer Trial

Greenwich LifeSciences said the delay in filing Form 10-K was due to accounting adjustments tied to stronger-than-expected patient enrollment in its Phase III trial to treat breast cancer.